Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H (HK:1276)
:1276
Want to see HK:1276 full AI Analyst Report?
1276 Stock Chart & Stats
HK$63.35
--
Market closed
HK$63.35
--
Day’s Range― - ―
52-Week RangeHK$51.30 - HK$95.20
Previous CloseN/A
VolumeN/A
Average Volume (3M)3.62M
Market Cap
HK$365.90B
Enterprise ValueHK$261.59B
Total Cash (Recent Filing)HK$46.26B
Total Debt (Recent Filing)HK$42.24M
Price to Earnings (P/E)38.5
Beta0.61
Next Earnings
Aug 17, 2026EPS Estimate
0.44Next Dividend Ex-DateN/A
Dividend Yield0.36%
Share Statistics
EPS (TTM)1.38
Shares Outstanding258,197,600
10 Day Avg. Volume2,417,952
30 Day Avg. Volume3,618,442
Financial Highlights & Ratios
PEG Ratio2.20
Price to Book (P/B)6.79
Price to Sales (P/S)13.15
P/FCF Ratio50.27
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$95.47Price Target Upside50.70% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)1.63
Revenue Forecast (FY)HK$41.45B
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetExtremely low debt relative to equity gives durable financial flexibility: it reduces solvency risk, supports continued R&D funding and capacity to withstand sector shocks, and enables strategic investments or partnerships without forcing capital raises that dilute shareholders.
Strong Cash GenerationHigh absolute operating and free cash flow provide a lasting capacity to fund clinical programs, manufacturing scale-up, capex, and shareholder returns internally. Even modest FCF growth still means the company can self-fund strategy execution and withstand cyclical pressures.
High Profitability And MarginsVery high gross margins and solid net income indicate structural pricing power or favorable product mix in specialty drugs. Durable margins support reinvestment into R&D, margin-backed earnings resilience, and buffer against competitive or pricing headwinds over the medium term.
Bears Say
Moderate Top-line GrowthTop-line expansion is modest, which limits leverage from scale and constrains long-term earnings upside if new product launches or geographic expansion falter. Sustained value creation will require either faster organic growth or successful innovation outperformance.
Modest Free Cash Flow GrowthWhile FCF is large in absolute terms, slow growth reduces the pace at which the firm can expand R&D intensity, add manufacturing capacity, or pursue acquisitions without reallocating existing capital, potentially slowing strategic progress versus faster-growing peers.
Reliance On Margin ExecutionCurrent profitability appears driven more by margin strength than rapid revenue gains. This creates vulnerability: if pricing, cost inflation, reimbursement, or competition erode margins, earnings and cash generation could decline materially absent renewed top-line momentum.
Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H News
1276 FAQ
What was Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H’s price range in the past 12 months?
Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H lowest stock price was HK$51.30 and its highest was HK$95.20 in the past 12 months.
What is Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H’s market cap?
Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H’s market cap is HK$365.90B.
When is Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H’s upcoming earnings report date?
Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H’s upcoming earnings report date is Aug 17, 2026 which is in 61 days.
How were Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H’s earnings last quarter?
Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H released its earnings results on Apr 23, 2026. The company reported HK$0.39 earnings per share for the quarter, beating the consensus estimate of HK$0.375 by HK$0.015.
Is Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H overvalued?
According to Wall Street analysts Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H’s price is currently Undervalued.
Does Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H pay dividends?
Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H pays a N/A dividend of HK$0.228 which represents an annual dividend yield of 0.36%. See more information on Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H dividends here
What is Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H’s EPS estimate?
Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H’s EPS estimate is 0.44.
How many shares outstanding does Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H have?
Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H has 258,197,600 shares outstanding.
What happened to Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H’s price movement after its last earnings report?
Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H reported an EPS of HK$0.39 in its last earnings report, beating expectations of HK$0.375. Following the earnings report the stock price went up 2.768%.
Which hedge fund is a major shareholder of Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H?
Currently, no hedge funds are holding shares in HK:1276
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
HK$95.47 (50.70% Upside)
HK$95.47 (50.70% Upside)
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Fundamentals
Return on Equity
14.56%
Trailing 12-Months
Asset Growth
47.03%
Trailing 12-Months
Company Description
Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H
Jiangsu Hengrui Pharmaceuticals Co.,Ltd, a pharmaceutical company, researches, develops, manufactures, and commercializes medicines to address unmet clinical needs in China and internationally. The company develops medicines in the areas of oncology, metabolic and cardiovascular, immunological and respiratory, neuroscience, pain management, infectious, respiratory system, hematological, ophthalmology, and autoimmune and other diseases. The company was founded in 1970 and is headquartered in Lianyungang, China.
Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H (1276) Earnings & Revenues
1276 Stock 12 Month Forecast
Average Price Target
HK$95.47
▲(50.70% Upside)
Technical Analysis
Sino Biopharmaceutical
―
Innovent Biologics
―
Akeso, Inc.
―
Hansoh Pharmaceutical Group Company Limited
―
BeOne Medicines Ltd
―
Options Prices
Currently, No data available
---